{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:01:04Z","timestamp":1788238864729,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K07953"],"award-info":[{"award-number":["19K07953"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) is a newly identified autoimmune demyelinating disorder that is often associated with acute disseminated encephalomyelitis and usually occurs postinfection or postvaccination. Here we report a case of MOGAD after mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. A previously healthy 68-year-old woman presented to our department with gradually worsening numbness on the right side of her face, which began 14 days after her second dose of an mRNA-1273 vaccination. The patient's brain MRI revealed a right cerebellar peduncle lesion with gadolinium enhancement, a typical finding of MOGAD. A neurological examination revealed paresthesia on her right V2 and V3 areas. Other neurological examinations were unremarkable. Laboratory workups were positive for serum MOG-IgG as assessed by live cell-based assays and the presence of oligoclonal bands in the cerebrospinal fluid (CSF). The patient's serum test results for cytoplasmic-antineutrophil cytoplasmic antibodies, perinuclear-cytoplasmic-antineutrophil cytoplasmic antibodies, GQ1b-antibodies, and aquaporin-4 antibodies (AQP4-IgG) were all negative. Tests for soluble interleukin (IL)-2 receptors in the serum, IL-6 in the CSF and skin pricks, and angiotensin converting enzyme tests were all unremarkable. The patient was diagnosed with MOGAD after receiving an mRNA SARS-CoV-2 vaccination. After two courses of intravenous methylprednisolone treatment, the patient's symptoms improved and her cerebellar peduncle lesion shrunk slightly without gadolinium enhancement. To date, there have only been two cases of monophasic MOGAD following SARS-CoV-2 vaccination, including both the ChAdOx1 nCOV-19 and mRNA-1273 vaccines, and the prognosis is generally similar to other typical MOGAD cases. Although the appearance of MOG antibodies is relatively rare in post-COVID-19\u2013vaccine demyelinating diseases, MOGAD should be considered in patients with central nervous system (CNS) demyelinating diseases after receiving a SARS-CoV-2 vaccine.<\/jats:p>","DOI":"10.3389\/fneur.2022.845755","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:09:22Z","timestamp":1646122162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuki","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayane","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Warita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-021-10780-7","article-title":"COVID-19 mRNA vaccination leading to CNS inflammation: a case series","author":"Khayat-Khoei","year":"2021","journal-title":"J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1212\/NXI.0000000000001080","article-title":"Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis","volume":"8","author":"Manzano","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","article-title":"A systematic review of cases of CNS demyelination following COVID-19 vaccination","volume":"362","author":"Ismail","year":"2022","journal-title":"J Neuroimmunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/jnnp-2020-324818","article-title":"Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases","volume":"92","author":"Matsumoto","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976-1977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1001\/jama.1984.03340440030022","article-title":"Swine flu vaccine and multiple sclerosis","volume":"251","author":"Kurland","year":"1984","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12016-010-8213-3","article-title":"Guillain-Barr\u00e9 syndrome-a classical autoimmune disease triggered by infection or vaccination","volume":"42","author":"Israeli","year":"2012","journal-title":"Clin Rev Allergy Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1212\/NXI.0000000000000954","article-title":"Incidence and impact of COVID-19 in MS: a survey from a Barcelona MS unit","volume":"8","author":"Sep\u00falveda","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1001","DOI":"10.1212\/NXI.0000000000001001","article-title":"COVID-19 among patients with multiple sclerosis: a systematic review","volume":"8","author":"Barzegar","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"656313","DOI":"10.3389\/fnhum.2021.656313","article-title":"Neuropsychiatric symptoms of COVID-19 explained by SARS-CoV-2 proteins' mimicry of human protein interactions","volume":"15","author":"Yapici-Eser","year":"2021","journal-title":"Front Hum Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic princibles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7224\/1537-2073.2018-104","article-title":"Case report: postvaccination anti-myelin oligodendrocyte glycoprotein neuromyelitis optica spectrum disorder: a case report and literature review of postvaccination demyelination","volume":"22","author":"Kumar","year":"2020","journal-title":"Int J MS Care."},{"key":"B19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10072-021-05761-7","article-title":"ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination","volume":"43","author":"Mumoli","year":"2021","journal-title":"Neurol Sci."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211057512","article-title":"MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination","author":"Dams","year":"2021","journal-title":"Mult Scler."},{"key":"B21","doi-asserted-by":"publisher","first-page":"653786","DOI":"10.3389\/fimmu.2021.653786","article-title":"Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222)","volume":"12","author":"Rom\u00e1n","year":"2021","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.845755\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:09:24Z","timestamp":1646122164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.845755\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":23,"alternative-id":["10.3389\/fneur.2022.845755"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.845755","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"845755"}}